Fennec Pharmaceuticals (FENC) Net Income towards Common Stockholders (2010 - 2025)
Fennec Pharmaceuticals (FENC) posted Net Income towards Common Stockholders of -$4.7 million for Q4 2025, down 656.66% on a QoQ basis from -$623000.0 in Q3 2025, and down 214.06% year-over-year from $4.1 million in Q4 2024.
Fennec Pharmaceuticals (FENC) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Fennec Pharmaceuticals' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$4.7 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 214.06% year-over-year to -$4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$9.7 million (down 5434.81% YoY) and the FY2025 annual result came in at $6.2 million, down 46.91% from the prior year.
- Net Income towards Common Stockholders was -$4.7 million for Q4 2025 at Fennec Pharmaceuticals, down from -$623000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $12.9 million in Q1 2024 and bottomed at -$8.0 million in Q3 2022.
- A 5-year average of -$3.3 million and a median of -$4.2 million in 2021 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 316.58% in 2024, while the deepest fall reached 222.47% in 2024.
- Fennec Pharmaceuticals' Net Income towards Common Stockholders stood at -$4.3 million in 2021, then slumped by 58.04% to -$6.7 million in 2022, then soared by 61.08% to -$2.6 million in 2023, then jumped by 42.67% to -$1.5 million in 2024, then plunged by 214.06% to -$4.7 million in 2025.
- Business Quant data shows FENC's Net Income towards Common Stockholders at -$4.7 million in Q4 2025, -$623000.0 in Q3 2025, and -$3.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Fennec Pharmaceuticals | 292.91 Mn | 256.13 Mn | 12.01 Mn | -4.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.71 Mn |
| Sep 30, 2025 | -623,000.00 |
| Jun 30, 2025 | -3.16 Mn |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Sep 30, 2024 | -5.71 Mn |
| Jun 30, 2024 | -5.51 Mn |
| Mar 31, 2024 | 12.91 Mn |
| Dec 31, 2023 | -2.62 Mn |
| Sep 30, 2023 | -1.77 Mn |
| Jun 30, 2023 | -5.38 Mn |
| Mar 31, 2023 | -5.96 Mn |
| Dec 31, 2022 | -6.73 Mn |
| Sep 30, 2022 | -8.05 Mn |
| Jun 30, 2022 | -5.06 Mn |
| Mar 31, 2022 | -3.60 Mn |
| Dec 31, 2021 | -4.26 Mn |
| Sep 30, 2021 | -4.22 Mn |
| Jun 30, 2021 | -3.96 Mn |
| Mar 31, 2021 | -4.91 Mn |